Literature DB >> 6472878

Mechanisms of protective immunity against S. mansoni infection in mice vaccinated with irradiated cercariae. VI. Influence of the major histocompatibility complex.

A Sher, S Hieny, S James.   

Abstract

Inbred mouse strains develop different levels of resistance to challenge infection with Schistosoma mansoni in response to vaccination with irradiated cercariae. The role of the major histocompatibility complex (MHC) in determining this genetic polymorphism in acquired resistance was investigated. Previous studies suggested that inbred mice bearing either the b or d MHC haplotypes develop a higher level of vaccine induced resistance than do mice with other MHC haplotypes. An analysis of an F1 cross between an H-2b strain (C57BL/6) and an H-2k strain (C3H/HeJ) indicated that the ability to develop high levels of immunity is inherited in a dominant fashion. In order to confirm that the development of high resistance is an MHC associated trait, B10, C3H, BALB and B6 congenic mice bearing different H-2 haplotypes were compared. On either the B10, B6, or BALB background, substitution of b or d with k or a MHC alleles resulted in a decreased level of vaccine induced immunity. The observed decreases were more pronounced in BALB and B6 than in B10 congenics suggesting an influence of background (non-MHC linked) genes on protective immunity. Similarly, C3H.SW (H-2b) mice developed a significantly higher level of acquired resistance than C3H/HeSn (H-2k) mice. Cross and backcross experiments between H-2b and H-2k B6 congenic mice confirmed the dominant inheritance of high resistance as well as the MHC linkage of the trait. These data indicate that the MHC locus exerts a quantitative influence on vaccine induced resistance in certain inbred mouse strains and provide further support for the concept that the protection elicited by irradiated cercariae is the manifestation of a specific host immune response.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6472878     DOI: 10.1111/j.1365-3024.1984.tb00804.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  8 in total

1.  The T-cell mediated immune response to Schistosoma mansoni. I. Generation of stage-specific, MHC-restricted proliferative T-cell clones to soluble egg antigens.

Authors:  N K Mak; C J Sanderson
Journal:  Immunology       Date:  1985-04       Impact factor: 7.397

2.  Genetic complementation of defects in vaccine-induced immunity against Schistosoma mansoni in P- and A-strain inbred mice.

Authors:  R Correa-Oliveira; S L James; A Sher
Journal:  Infect Immun       Date:  1988-03       Impact factor: 3.441

3.  Murine Taenia crassiceps cysticercosis: H-2 complex and sex influence on susceptibility.

Authors:  E Sciutto; G Fragoso; M L Diaz; F Valdez; R M Montoya; T Govezensky; C Lomeli; C Larralde
Journal:  Parasitol Res       Date:  1991       Impact factor: 2.289

4.  MHC heterozygosity confers a selective advantage against multiple-strain infections.

Authors:  Dustin J Penn; Kristy Damjanovich; Wayne K Potts
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

5.  Evidence for the segregation of a major gene in human susceptibility/resistance to infection by Schistosoma mansoni.

Authors:  L Abel; F Demenais; A Prata; A E Souza; A Dessein
Journal:  Am J Hum Genet       Date:  1991-05       Impact factor: 11.025

6.  Major histocompatibility complex heterozygote superiority during coinfection.

Authors:  Erin E McClelland; Dustin J Penn; Wayne K Potts
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

7.  Defective immunoglobulin M responses to vaccination or infection with Schistosoma mansoni in xid mice.

Authors:  R Correa-Oliveira; A Sher
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

8.  The importance of immune gene variability (MHC) in evolutionary ecology and conservation.

Authors:  Simone Sommer
Journal:  Front Zool       Date:  2005-10-20       Impact factor: 3.172

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.